← Evidence map

ArticleCureus2026

Comparative Gynecological Safety of the Dual GIP/GLP-1 Receptor Agonist Tirzepatide vs. the GLP-1 Receptor Agonist Semaglutide: A Real-World Pharmacovigilance Analysis (2022-2025).

Hima Bindu MakkenaPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

2 papers cite it

2026

this papercites it

Comparative Gynecological Safety of the Dual GIP/GLP-1 Receptor Agonist Tirzepatide vs. the GLP-1 Receptor Agonist Semaglutide: A Real-World Pharmacovigilance Analysis (2022-2025). | OpenQuestion